BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

India Upholds Cancellation of Johnson & Johnson (JNJ) Plant License


6/25/2013 7:38:45 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

In another blow to Johnson & Johnson’s efforts to remake its reputation after numerous manufacturing problems, the Maharashtra government in western India upheld a decision to cancel its license to manufacture cosmetics products* at a facility in suburban Mumbai. Last March, the local Food and Drug Administration cancelled the license after finding 15 batches of baby talcum power made at a plant in Mulund in 2007 were sterilized using ethylene oxide, a chemical that is believed to cause cancer, nausea and vomiting. The regulator alleged that J&J did not register the process and failed to conduct tests to check for traces of ethylene oxide in the batches of powder. "The company did not have data to check whether traces of ethylene oxide did not remain in the powder, as it is highly carcinogenic,” Maharashtra FDA commish Mahesh Zagde tells The Business Standard. “The company released small packs in the market and, in effect, exposed equal number of babies to carcinogenic substances. This is highly objectionable, irresponsible and illegal.”

Help employers find you! Check out all the jobs and post your resume.


Read at Pharmalot

Pharmalot
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES